Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Nizar J. Bahlis, Roman Hajek, Reuben Benjamin, Tuphan K. Dolai, Dinesh K. Sinha, Christopher P. Venner, Mamta Garg, Mercedes Gironella, Artur JurczyszynPawel Robak, Monica Galli, Craig Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don A. Stevens, Supratik Basu, Anna M. Liberati, Hang Quach, Vesselina S. Goranova-Marinova, Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Phillipe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Facon, Maria V. Mateos, Michele Cavo, Donna Reece, Larry D. Anderson, Jean Richard Saint-Martin, Jacqueline Jeha, Anita A. Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Meletios A. Dimopoulos, Paul G. Richardson, Sosana Delimpasi

Research output: Contribution to journal › Article › peer-review

172 Scopus citations

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Fingerprint

Medicine & Life Sciences